BioNano Genomics, Inc. WT EXP 082123
BNGOW
NASDAQ Capital Market0.00
USD
+0.00
- -
CIK
0001411690
ISIN
US09075F4046
CUSIP
09075F404
Return %
Stock
S&P500
1Y
-99.01
18.21
3Y
-97.83
64.38
5Y
-99.86
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 98
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 9540 Towne Centre Drive San Diego DE United States of America 92121
- IPO Date
- Sep 21, 2018
- CIK
- 0001411690
- Website
- bionanogenomics.com
- Similar Companies
- Business
- BioNano Genomics, Inc. specializes in genome analysis solutions primarily through its flagship Saphyr system, which provides ultra-sensitive and ultra-specific structural variation detection using optical genome mapping (OGM) technology. The company manufactures and sells OGM instruments, consumables including nanochannel array flowcells, and proprietary genome analysis software such as VIA and Solve. Additionally, it offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology, and operates diagnostic testing services through its subsidiary Lineagen, Inc. BioNano Genomics serves research and clinical markets globally with operations spanning the Americas, EMEA, and Asia Pacific, generating the majority of revenue from the EMEA region. Founded in 2006 and headquartered in San Diego, California, the company focuses on accelerating discovery in genetic diseases, cancer research, and clinical genomics. Recent major changes at BioNano Genomics include its January 2025 completion of a $10 million registered direct offering and ongoing capital raises via ATM sales to support growth initiatives. It also acquired Lineagen, Inc. in 2023, expanding its offerings to include CLIA-certified OGM-based diagnostic testing services and enhancing its clinical market presence. The company continuously updates its genome analysis software platforms, recently releasing new versions of VIA and Solve software and upgrading its Stratys Compute Server to improve data analysis. Notably, BioNano demonstrated expanding adoption of OGM technology with growing system installations and published studies validating OGM’s utility in cancer biomarker analysis and overcoming limitations of targeted RNA sequencing in leukemia. These developments underscore its strategic shift toward integrated genomic solutions combining OGM with next-generation sequencing for comprehensive genome assessment.